BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable ...

In-vitro fertilisation, or IVF, is often seen as an overwhelming process. But when broken down step by step, it's a carefully ...

The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.

Franklin Lakes, New Jersey Thursday, July 24, 2025, 14:00 Hrs [IST] ...

Pune-based health care company IntegriMedical is rethinking drug delivery with its needle-free injection system ...

Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

BD (NYSE:BDX) today announced the first pharma-sponsored combination product clinical trial using its wearable injector technology.

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with ...

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, ...

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Treatments for uveitic macular edema, including systemic and local options, were among the topics debated at the Congress on Controversies in Ophthalmology.